tetano
Editor, Senior Moderator
iScience
. 2022 Sep 28;105193.
doi: 10.1016/j.isci.2022.105193. Online ahead of print.
Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern
Hadas Cohen-Dvashi[SUP] 1 [/SUP], Jonathan Weinstein[SUP] 2 [/SUP], Michael Katz[SUP] 1 [/SUP], Maayan Ashkenazy-Eilon[SUP] 1 [/SUP], Yuval Mor[SUP] 1 [/SUP], Amir Shimon[SUP] 1 [/SUP], Hagit Achdout[SUP] 3 [/SUP], Hadas Tamir[SUP] 3 [/SUP], Tomer Israely[SUP] 3 [/SUP], Romano Strobelt[SUP] 4 [/SUP], Maya Shemesh[SUP] 2 [/SUP], Liat Stoler-Barak[SUP] 5 [/SUP], Ziv Shulman[SUP] 5 [/SUP], Nir Paran[SUP] 3 [/SUP], Sarel Jacob Fleishman[SUP] 2 [/SUP], Ron Diskin[SUP] 1 [/SUP]
Affiliations
Abstract
Blocking the interaction of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with its angiotensin-converting enzyme 2 (ACE2) receptor was proved to be an effective therapeutic option. Various protein binders as well as monoclonal antibodies that effectively target the receptor-binding domain (RBD) of SARS-CoV-2 to prevent interaction with ACE2 were developed. The emergence of SARS-CoV-2 variants that accumulate alterations in the RBD can severely affect the efficacy of such immunotherapeutic agents, as is indeed the case with Omicron that resists many of the previously isolated monoclonal antibodies. Here, we evaluate an ACE2-based immunoadhesin that we have developed early in the pandemic against some of the recent variants of concern (VoCs), including the Delta and the Omicron variants. We show that our ACE2-immunoadhesin remains effective in neutralizing these variants, suggesting that immunoadhesin-based immunotherapy is less prone to escape by the virus and has a potential to remain effective against future VoCs.
. 2022 Sep 28;105193.
doi: 10.1016/j.isci.2022.105193. Online ahead of print.
Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern
Hadas Cohen-Dvashi[SUP] 1 [/SUP], Jonathan Weinstein[SUP] 2 [/SUP], Michael Katz[SUP] 1 [/SUP], Maayan Ashkenazy-Eilon[SUP] 1 [/SUP], Yuval Mor[SUP] 1 [/SUP], Amir Shimon[SUP] 1 [/SUP], Hagit Achdout[SUP] 3 [/SUP], Hadas Tamir[SUP] 3 [/SUP], Tomer Israely[SUP] 3 [/SUP], Romano Strobelt[SUP] 4 [/SUP], Maya Shemesh[SUP] 2 [/SUP], Liat Stoler-Barak[SUP] 5 [/SUP], Ziv Shulman[SUP] 5 [/SUP], Nir Paran[SUP] 3 [/SUP], Sarel Jacob Fleishman[SUP] 2 [/SUP], Ron Diskin[SUP] 1 [/SUP]
Affiliations
- PMID: 36188189
- PMCID: PMC9514956
- DOI: 10.1016/j.isci.2022.105193
Abstract
Blocking the interaction of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with its angiotensin-converting enzyme 2 (ACE2) receptor was proved to be an effective therapeutic option. Various protein binders as well as monoclonal antibodies that effectively target the receptor-binding domain (RBD) of SARS-CoV-2 to prevent interaction with ACE2 were developed. The emergence of SARS-CoV-2 variants that accumulate alterations in the RBD can severely affect the efficacy of such immunotherapeutic agents, as is indeed the case with Omicron that resists many of the previously isolated monoclonal antibodies. Here, we evaluate an ACE2-based immunoadhesin that we have developed early in the pandemic against some of the recent variants of concern (VoCs), including the Delta and the Omicron variants. We show that our ACE2-immunoadhesin remains effective in neutralizing these variants, suggesting that immunoadhesin-based immunotherapy is less prone to escape by the virus and has a potential to remain effective against future VoCs.